Updates on ankylosing spondylitis: pathogenesis and therapeutic agents
Journal of Rheumatic Diseases
; : 220-233, 2023.
Article
en En
| WPRIM
| ID: wpr-1001541
Biblioteca responsable:
WPRO
ABSTRACT
Ankylosing spondylitis (AS) is an autoinflammatory disease that manifests with the unique feature of enthesitis. Gut microbiota, HLA-B*27, and biomechanical stress mutually influence and interact resulting in setting off a flame of inflammation. In the HLAB*27 positive group, dysbiosis in the gut environment disrupts the barrier to exogenous bacteria or viruses. Additionally, biomechanical stress induces inflammation through enthesial resident or gut-origin immune cells. On this basis, innate and adaptive immunity can propagate inflammation and lead to chronic disease. Finally, bone homeostasis is regulated by cytokines, by which the inflamed region is substituted into new bone. Agents that block cytokines are constantly being developed to provide diverse therapeutic options for preventing the progression of inflammation. In addition, some antibodies have been shown to distinguish disease selectively, which support the involvement of autoimmune immunity in AS. In this review, we critically analyze the complexity and uniqueness of the pathogenesis with updates on the findings of immunity and provide new information about biologics and biomarkers.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
En
Revista:
Journal of Rheumatic Diseases
Año:
2023
Tipo del documento:
Article